search
Back to results

Muscle Vibration and Fatigue in Patients With MS

Primary Purpose

Multiple Sclerosis

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
vibra plus
Sponsored by
IRCCS Centro Neurolesi "Bonino-Pulejo"
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Multiple Sclerosis

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Definite diagnosis of Multiple Sclerosis according to the McDonald criteria; Evidence of fatigue symptoms; Age between 20 and 60; Score on the EDSS scale between 1 and 5.5; Signed informed consent. Exclusion Criteria: Pregnancy; Presence of cardiac pacemaker or other implants; Malignant neoplasms; Presence of cardiac, pulmonary, or musculoskeletal comorbidities that contraindicate physical exercise; Presence of non-healed wounds; Severe visual and/or hearing impairment;

Sites / Locations

  • Irccs Neurolesi Centro Bonino PulejoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

standard care + vibra plus

Standard care

Arm Description

patients will undergo treatment with the vibra plus device on top of traditional rehabilitation

patients undergo a traditional rehabilitation program

Outcomes

Primary Outcome Measures

mobility
changes in motricity index
postural control
changes in Tinetti's scale
postural control
changes in Berg's scale

Secondary Outcome Measures

fatigue
changes in the Fatigue Severity Scale (FSS)
fatigue
changes in the Modified Fatigue Impact Scale (MFIS)
fatigue
changes in the Fatigue Scale for Motor and Cognitive Functions (FSMC)
fatigue
changes in the Borg Scale
fatigue
changes in the Medical Research Council Scale (MRC)
quality of life
changes in the Multiple Sclerosis Quality of Life-54 (MSQOL-54) scale
quality of life
changes in the Coping Orientation to Problems Experienced (COPE) questionnaire

Full Information

First Posted
March 14, 2023
Last Updated
April 4, 2023
Sponsor
IRCCS Centro Neurolesi "Bonino-Pulejo"
search

1. Study Identification

Unique Protocol Identification Number
NCT05783999
Brief Title
Muscle Vibration and Fatigue in Patients With MS
Official Title
Role of Muscle Vibration in Improving the Sense of Fatigue in Patients With Multiple Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 28, 2021 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
IRCCS Centro Neurolesi "Bonino-Pulejo"

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Multiple Sclerosis is the most common cause of neurologic chronic disability in young adults. Fatigue is one of the principal symptom in this disease. In the past it was demonstrated how, with appropriate frequencies and amplitude of vibration, it is possible both to select the activated afferents, and to determine the frequency of action potentials sent to the Central Nervous System. The purpose of this study is to verify how the use of vibrations can induce positive effects on the mobility and postural control of patients with MS, as well as reduce fatigue. The study is an interventional type. The subjects are undergoing to baseline examinations (T0) including 3D gait analysis (using a BTS system), stabilometric analysis, and a battery of neuropsychological assessments. Subsequently, eligible subjects are undergoing to intensive multidisciplinary training for a total of 5 sessions per week for 4 weeks, with a total of 20 treatment sessions. The experimental group receive additional vibration treatment. At the end of the treatment cycle (T1), the patients will undergo the same evaluation tests as at baseline. The Clinical and instrumental exams used for this study (as per normal clinical practice) are: Expanded Disability Status Scale (EDSS), Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS), Fatigue Scale for Motor and Cognitive Functions (FSMC), Borg Scale, Medical Research Council Scale (MRC), 6 minutes walking test. The Psychological Assessment Battery used are: Multiple Sclerosis Quality of Life-54 (MSQOL-54) scale, Beck Depression Inventory-II, Coping Orientation to Problems Experienced (COPE). Sample size: The sample consist of patients with MS admitted to the C.A.R.E.N. or Casazza facilities of the IRCCS Centro Neurolesi Bonino-Pulejo in Messina. Twenty eligible subjects recruited and treated with traditional rehabilitation approach plus vibrational therapy. The results will be compared to those obtained from a group of 20 patients who have undergone a traditional rehabilitation treatment without the application of vibrations and who will represent the control group.
Detailed Description
Multiple Sclerosis is the most common cause of neurologic chronic disability in young adults. Fatigue is one of the principal symptom in this disease. Fatigue in a subject with MS is present every day, gets worse as the day progresses, with the heat and humidity, it is sudden and more severe than normal, it interferes with physical performance. Fatigue is prevalent in the MS population and is a significant health problem, negatively impacting activities of daily living, ability to work, social life and quality of life. In 1963 it was demonstrated how mechanical vibration, applied to a single muscle, at suitable amplitudes and frequencies, was capable of selectively and differentially activating primary (Ia), secondary (IIb) or GTO spindle afferents, depending on the characteristics of the stimulus. So with appropriate frequencies and amplitude of vibration, it is possible both to select the activated afferents, and to determine the frequency of action potentials sent to the Central Nervous System. The purpose of this study is to verify how the use of vibrations can induce positive effects on the mobility and postural control of patients with MS, as well as reduce fatigue. The study is an interventional type. The subjects are undergoing to baseline examinations (T0) including 3D gait analysis (using a BTS system), stabilometric analysis, and a battery of neuropsychological assessments. Subsequently, eligible subjects are undergoing to intensive multidisciplinary training for a total of 5 sessions per week for 4 weeks, with a total of 20 treatment sessions. The experimental group receive additional vibration treatment. At the end of the treatment cycle (T1), the patients will undergo the same evaluation tests as at baseline. The Clinical and instrumental exams used for this study (as per normal clinical practice) are: Expanded Disability Status Scale (EDSS), Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS), Fatigue Scale for Motor and Cognitive Functions (FSMC), Borg Scale, Medical Research Council Scale (MRC), 6 minutes walking test. The Psychological Assessment Battery used are: Multiple Sclerosis Quality of Life-54 (MSQOL-54) scale, Beck Depression Inventory-II, Coping Orientation to Problems Experienced (COPE). Sample size: The sample consist of patients with MS admitted to the C.A.R.E.N. or Casazza facilities of the IRCCS Centro Neurolesi Bonino-Pulejo in Messina. Twenty eligible subjects recruited and treated with traditional rehabilitation approach plus vibrational therapy. The results will be compared to those obtained from a group of 20 patients who have undergone a traditional rehabilitation treatment without the application of vibrations and who will represent the control group. A descriptive analysis of the two groups will be performed for clinical and socio-demographic variables. The Shapiro-Wilk test will be applied to assess the distribution of variables. Subsequently, continuous variables will be expressed as mean±sd or median and I-III quartile, while categorical variables in frequency and percentages. An intra-group analysis will be carried out to compare both clinical and instrumental scores between T0 and T1 in each group using either T-Student or Wilcoxon for paired data, and a Pearson correlation or Spearman rank correlation to evaluate the relationship between clinical scales and instrumental data. The inter-group analysis will be applied to compare both clinical and instrumental scores between the groups at T0 and T1 using either a parametric test (T-Student for unpaired data) or a non-parametric test (U-Mann Whitney). The analysis will be performed using the open-source software R3.0. A confidence interval of 95% with a 5% alpha error will be considered. Statistical significance will be set at p<0.05. The principal investigator (PI) will conduct the study in accordance with good clinical practice (GCP) guidelines and current regulations, and in accordance with the current version of the Declaration of Helsinki. All study participants will sign informed consent in accordance with current regulations. The study investigator will inform the subject that participation in the protocol is voluntary and that refusal will not in any way affect the relationship with the researcher. Before enrollment in the study, each subject will receive a clear explanation of the nature and purpose of the study from the investigator. A clear information sheet outlining all salient aspects will also be provided in hard copy to the subject, who will have the opportunity to ask any questions and raise any concerns regarding the contents. Additionally, the subject will be given ample time to decide whether to participate in the study before signing the informed consent in duplicate. The original signed informed consent will be retained by the investigator. Before carrying out any examination provided by this protocol, patients will also provide all authorizations required by law (European Regulation 2016/679, Legislative Decree 196/2003 modified by Legislative Decree no. 101 of 10/08/2018) and by the provisions of the Privacy Guarantor. In accordance with good clinical practice rules, each subject will be uniquely identified by a code, which will be the subject identifier for the entire duration of the studY. The experimenter will wait for approval from the Ethics Committee. The study in question will be conducted according to the attached protocol, in compliance with the expected timelines, the Declaration of Helsinki (1964 and subsequent amendments), in compliance with Good Clinical Practice guidelines, and in accordance with current regulations. The study does not involve any additional costs for the institution, nor any external sources of funding of any kind. There is no compensation planned for the study's principal investigator or the involved experimenters. The institution and experimenters are covered by adequate insurance coverage for any damages that may arise from the experimentation. The proposer agrees to prepare a final report at the conclusion of the study and to make the results publicly available.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
standard care + vibra plus
Arm Type
Experimental
Arm Description
patients will undergo treatment with the vibra plus device on top of traditional rehabilitation
Arm Title
Standard care
Arm Type
No Intervention
Arm Description
patients undergo a traditional rehabilitation program
Intervention Type
Device
Intervention Name(s)
vibra plus
Intervention Description
the device is applied to the patient's lower limbs and generates an active flow of vibrations that may reduce fatigue
Primary Outcome Measure Information:
Title
mobility
Description
changes in motricity index
Time Frame
12 months
Title
postural control
Description
changes in Tinetti's scale
Time Frame
12 months
Title
postural control
Description
changes in Berg's scale
Time Frame
12 months
Secondary Outcome Measure Information:
Title
fatigue
Description
changes in the Fatigue Severity Scale (FSS)
Time Frame
12 months
Title
fatigue
Description
changes in the Modified Fatigue Impact Scale (MFIS)
Time Frame
12 months
Title
fatigue
Description
changes in the Fatigue Scale for Motor and Cognitive Functions (FSMC)
Time Frame
12 months
Title
fatigue
Description
changes in the Borg Scale
Time Frame
12 months
Title
fatigue
Description
changes in the Medical Research Council Scale (MRC)
Time Frame
12 months
Title
quality of life
Description
changes in the Multiple Sclerosis Quality of Life-54 (MSQOL-54) scale
Time Frame
12 months
Title
quality of life
Description
changes in the Coping Orientation to Problems Experienced (COPE) questionnaire
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Definite diagnosis of Multiple Sclerosis according to the McDonald criteria; Evidence of fatigue symptoms; Age between 20 and 60; Score on the EDSS scale between 1 and 5.5; Signed informed consent. Exclusion Criteria: Pregnancy; Presence of cardiac pacemaker or other implants; Malignant neoplasms; Presence of cardiac, pulmonary, or musculoskeletal comorbidities that contraindicate physical exercise; Presence of non-healed wounds; Severe visual and/or hearing impairment;
Facility Information:
Facility Name
Irccs Neurolesi Centro Bonino Pulejo
City
Messina
State/Province
Sicily
ZIP/Postal Code
98121
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roberta Cellini, MD
Phone
09060128100
Email
roberta.cellini@irccsme.it

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Muscle Vibration and Fatigue in Patients With MS

We'll reach out to this number within 24 hrs